Blood
Articles in this Issue
Clinical characteristics and outcomes in patients with SH2B3-mutated erythrocytosis: A retrospective cohort study
Abstract Introduction: Polycythemia vera (PV) is a primary etiology of erythrocytosis most often caused by mutations in JAK2. Other primary...
Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients
Abstract Background: The introduction of tyrosine kinase inhibitors (TKIs) has improved the management of chronic myeloid leukemia (CML), mak...
Venous thromboembolism and bleeding rates in pregnant and postpartum patients with sickle cell disease
Abstract Background: Venous thromboembolism (VTE) and postpartum hemorrhage (PPH) are major causes of increased maternal morbidity observed...
An analysis of clonal dynamics in patients with indolent systemic mastocytosis treated with avapritinib in the pioneer study
Abstract Introduction: Systemic mastocytosis (SM) is a hematologic neoplasm driven by the KIT D816V mutation in ~95% of cases. Avapritinib,...
Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies
Abstract Background: BAF complexes control chromatin accessibility to regulate gene expression programs important for cellular proliferation...
Comparison of outcomes in antiphospholipid syndrome diagnosed by ISTH versus EULAR criteria
Abstract Introduction Antiphospholipid syndrome (APS) is a hematologic autoimmune condition characterized by the persist...
Real-world efficacy and safety of mezigdomide-dexamethasone in heavily pre-treatred multiple myeloma patients: An Italian case series
Abstract Introduction Heavily pre-treated multiple myeloma (MM) patients have very poor outcomes and limited survival. Mezigdomide, a novel...
Grndma: Initial reports from an adult sickle cell registry in Malawi
Abstract Sickle Cell Disease (SCD) is the most common monogenic disorder in the world. It is caused by a mutation in the β-globin subunit of...
PRL-3 enhances multiple myeloma cell survival in acidic microenvironments via metabolic adaptation and pH regulation.
Abstract Background Phosphatase of Regenerating Liver-3 (PRL-3) is frequently upregulated in cancers, particularly in mu...
Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T
Abstract Background: Relapse following auto CD19-directed CAR T-cell therapy remains a major challenge in LBCL as these patients (pts) have...
Phase II trial of maintenance therapy with iberdomide after autologous hematopoietic cell transplant for patients with multiple myeloma previously treated with lenalidomide
Abstract Background Lenalidomide maintenance after upfront autologous hematopoietic cell transplantation (aHCT) has improved progression free...
Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial
Abstract Background: FLAG based therapy, especially with gemtuzumab ozogamicin (GO) has led to excellent relapse free (RFS) and overall surv...
CBX–663, a novel TCR-mimetic T-cell engager targeting a telomerase reverse transcriptase (TERT) peptide-HLA complex, that exhibits potent efficacy against AML cells
Abstract Telomerase Reverse Transcriptase (TERT) is an oncogenic driver highly expressed in ~90% of all tumors, including hematologic malign...
Phytosphingosine alleviates acute gvhd by inducing th cell differentiation to Tr1 through GPR120/IL-10 axis
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for a broad range of hematologic diseas...
High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia
Abstract INTRODUCTION: The MDS1 and EVI1 Complex Locus (MECOM), located at chromosome 3q26.2 is rearranged (MECOM-R) in ~1.5% of Acute Myelo...
Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy
Abstract Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated clinical efficacy in treating chronic lymphocytic leukemia/sma...
Phase 2 study of brexu-cel in minimal residual disease positive B-cell acute lymphoblastic leukemia
Abstract Background and Significance: Recent data suggest that identification of low burden disease (minimal residual disease, MRD) following...
Long non-coding RNA (lncRNA) expression signatures distinguish drug response phenotypes in multiple myeloma cell line models
Abstract Introduction: Long non-coding RNAs (lncRNAs) have emerged as critical regulators of gene expression and cellular phenotype in hemat...
The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication
Abstract Background Survival of patients with high or very high-risk myelodysplastic neoplasm (MDS) by IPSS-M is decreased due to transforma...
Comprehensive profiling of highly heterogeneous FLT3-ITD variants reveals distinct drug response patterns in AML
Abstract Introduction: Internal tandem duplications (ITDs) in the FLT3 gene occur in ~25% of adult AML patients and are associated with rela...
In Vivo modeling of leukemic evolution in ELANE-associated severe congenital neutropenia
Abstract Congenital neutropenia (CN) is a heterogeneous inherited preleukemia bone marrow syndrome, with autosomal dominant mutations in ELA...
Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma
Abstract Introduction: Anti-CD20–based therapies are the standard-of-care first-line treatment for advanced follicular lymphoma (FL), but mo...
Real-world treatment patterns and survival in splenic marginal zone lymphoma: A national analysis in the rituximab era
Abstract Background: Splenic Marginal Zone Lymphoma (SMZL) is a rare B-cell lymphoma with heterogeneous clinical behavior. Although typicall...
Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial
Abstract Introduction: High-risk mantle cell lymphoma (MCL) is a molecularly complex, heterogeneous disease with frequent relapses and limit...
Tracking MRD in multiple myeloma: Soluble BCMA reflects flow cytometry changes
Abstract Background: Soluble B-cell maturation antigen (sBCMA) is increasingly recognized as a quantitative biomarker of tumor burden and di...